drugset / Trial / NCT07501156
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the feasibility, safety and efficacy of H3K27M-specific engineered immune effector (EIE) therapy in patients with high-risk, H3K27M-positive diffuse midline glioma/diffuse intrinsic pontine glioma. Another goal of the study is to learn more about the function of the anti-H3K27M EIE cells and their persistency in patients.
Timeline
- Start
- 2026-03-18
- Primary completion
- 2029-12-31
- Completion
- 2030-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | H3K27M-EIEs | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | H3K27M-EIEs | Cell therapy | 1e+07 cells/kg | Intravenous |